Improving TNM-10 staging for nasopharyngeal cancer worldwide
Official title: International Collaborative Study to Develop the AJCC/UICC TNM Version-Ten for Nasopharyngeal Cancer
Run by The University of Hong Kong-Shenzhen Hospital · NCT07013461 · Data updated 2026-11-12
This project will collect data from people with nasopharyngeal cancer treated in 2025–2026 to see if updating the TNM-10 anatomical staging and adding blood and molecular markers can better predict outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 5000 (estimated) |
| Sponsor | The University of Hong Kong-Shenzhen Hospital Academic / other |
| Locations | 1 site (Shenzhen, Guangdong) |
| Status | Recruiting |
| Started | January 9, 2026 |
| Main results expected | December 31, 2031 |
| Study ends | December 31, 2031 |
| Registry record updated | May 4, 2026 |
| Trial ID | NCT07013461 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are all patients with histologically confirmed nasopharyngeal carcinoma who receive treatment at participating centers between October 1, 2025 and September 30, 2026.
✕Probably not a fit
Patients with non-epithelial nasopharyngeal tumors (for example lymphoma, sarcoma, mucosal melanoma, salivary-type tumors, or bone/cartilage tumors) are excluded and would not be expected to benefit from the NPC-focused staging updates.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an international, multicenter prospective observational effort enrolling consecutive histologically confirmed nasopharyngeal carcinoma patients treated between 1 October 2025 and 30 September 2026. The study will harmonize universally assessable anatomical TNM parameters across centers and combine them with non-anatomical factors such as circulating EBV DNA and hematologic biomarkers. Data will come from high-incidence regions (including Mainland China and Hong Kong) and from non-endemic areas to provide broadly applicable evidence. The overall aim is to generate high-quality prospective data to inform development of the next AJCC/UICC TNM Version-Ten for NPC.
Why it matters
Potential benefit: If successful, this could give clinicians more accurate staging and personalized treatment guidance, helping to reduce under- or overtreatment.
How similar studies have gone: Retrospective studies have supported the prior TNM-9 updates and shown prognostic value for EBV DNA and blood biomarkers, but a large international prospective effort to integrate these factors into a formal TNM-10 framework is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All histologically confirmed nasopharyngeal carcinoma treated between 1 Oct 2025 and 30 Sep 2026 Exclusion Criteria: * Non-epithelial tumors of nasopharynx (including lymphoma, sarcoma of soft tissue, bone/cartilagetumors. mucosal melanoma, salivary type tumors)
Where it's running
-
The University of Hong Kong-Shenzhen Hospital
Shenzhen, Guangdong, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Nanocrystalline Megestrol Acetate to Help Appetite During Chemoradiotherapy in Nasopharyngeal Carcinoma
This phase 3 trial tests whether taking nanocrystalline megestrol acetate can help people with nasopharyngeal carcinoma who are receiving chemoradiotherapy to keep their appetite and weight better than placebo.
-
Becotatug Vedotin plus Anti-PD-1 as maintenance for recurrent/metastatic NPC
This phase 3 trial tests whether adding becotatug vedotin to an anti-PD-1 therapy as maintenance can help people with recurrent or metastatic nasopharyngeal cancer who have stable disease after initial treatment.
-
Intratumoral EDS01 plus toripalimab for recurrent or metastatic head and neck cancer
This phase 1 study tests whether directly injecting a gene‑therapy endostatin product (EDS01) into a tumor, together with the PD-1 inhibitor toripalimab, is safe and shows early signs of activity in adults with recurrent or metastatic head and neck cancer after platinum therapy.
-
Maintenance immunotherapy with deferred salvage radiotherapy after response to chemoimmunotherapy in recurrent nasopharyngeal cancer
This study tests whether continuing immunotherapy and delaying salvage radiotherapy after an initial chemoimmunotherapy response can help people with unresectable recurrent nasopharyngeal cancer live longer and feel better.
-
Becotatug vedotin added to radiation and adjuvant therapy for locally advanced nasopharyngeal cancer with a poor response to induction chemo‑immunotherapy
This will test whether adding becotatug vedotin during radiation and afterward helps people with locally advanced nasopharyngeal cancer who had a suboptimal response to induction chemotherapy combined with immunotherapy.
-
IMRT-only treatment for stage IB nasopharyngeal cancer without high-risk features
This trial will test whether IMRT alone can control stage IB nasopharyngeal cancer without high-risk features in adults aged 18–70.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.